Foghorn Therapeutics Inc.
NASDAQ:FHTX

Watchlist Manager
Foghorn Therapeutics Inc. Logo
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Watchlist
Price: 4.93 USD -4.09%
Market Cap: 274.1m USD
Have any thoughts about
Foghorn Therapeutics Inc.?
Write Note

Foghorn Therapeutics Inc.
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Foghorn Therapeutics Inc.
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Accounts Payable
$6.3m
CAGR 3-Years
19%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accounts Payable
$30.5B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Payable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accounts Payable
$18.9B
CAGR 3-Years
153%
CAGR 5-Years
80%
CAGR 10-Years
35%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Payable
$4B
CAGR 3-Years
215%
CAGR 5-Years
112%
CAGR 10-Years
59%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Payable
$497.3m
CAGR 3-Years
5%
CAGR 5-Years
8%
CAGR 10-Years
27%
No Stocks Found

Foghorn Therapeutics Inc.
Glance View

Market Cap
274.1m USD
Industry
Biotechnology

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 119 full-time employees. The company went IPO on 2020-10-23. The firm's Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is initially focused on oncology. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, which is evaluating in separate Phase I studies in metastatic uveal melanoma and relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company is also developing FHD-609, a protein degrader, to treat synovial sarcoma is in phase I study. The firm is also engaged in developing additional programs targeting populations that include selective BRM and selective ARID1B modulators. Foghorn Securities Corporation is its subsidiary.

FHTX Intrinsic Value
6.13 USD
Undervaluation 20%
Intrinsic Value
Price

See Also

What is Foghorn Therapeutics Inc.'s Accounts Payable?
Accounts Payable
6.3m USD

Based on the financial report for Dec 31, 2023, Foghorn Therapeutics Inc.'s Accounts Payable amounts to 6.3m USD.

What is Foghorn Therapeutics Inc.'s Accounts Payable growth rate?
Accounts Payable CAGR 5Y
26%

Over the last year, the Accounts Payable growth was 16%. The average annual Accounts Payable growth rates for Foghorn Therapeutics Inc. have been 19% over the past three years , 26% over the past five years .

Back to Top